Caffeine's stimulant properties were used to test a proposed processing schema for children's processing stages in the equiprobable auditory go/no-go task. Active control-related ERP components were hypothesized to be differentially enhanced by caffeine. Caffeine (80 mg) was administered in a counterbalanced, randomized, double-blind, placebo-controlled, cross-over study of 24 children, aged 8-12 years. Four blocks of an equiprobable auditory go/no-go task were completed on each of two occasions, while on or off caffeine. ERP data sets from each condition (caffeine/go, placebo/go, caffeine/no-go, placebo/no-go) were subjected to separate temporal PCAs with extraction and varimax rotation of all components. Caffeine significantly reduced reaction time and go omission errors, and enhanced go PN, N2c, and P3b, and no-go N1-1 and N2b. This selective enhancement of different go/no-go components by caffeine matched the predicted amplification of biomarkers of children's active control processing in this task. Some unexpected findings also support further refinements in the child processing schema.
6 participants and experimenters, and paradigm differences. Barry et al. (2007) attempted to optimise control of such variables using peak-picked ERP data from a randomised double-blind placebocontrolled repeated-measures cross-over study. It was found that 250 mg of caffeine (cf. placebo) reduced reaction time (RT), but had no effects on omission or commission errors. There were also focal increases in the amplitudes of Go P1, P2, and P3b, but no impact on Go N1 or N2. Caffeine had no effect on NoGo component amplitudes, and no latency effects on Go or NoGo components.
That is, caffeine's arousal effects appeared to be confined to the active Go processing and its ERP components. This is compatible with the conclusion of Tieges, Snel, Kok, and Ridderinkhof (2009) , based on effects in a range of inhibitory tasks, that caffeine "has little effect on… inhibitory control" (P. 325).
Our temporal PCA study of caffeine effects in the Go/NoGo ERPs of another adult group (Barry, De Blasio, & Cave, 2014) followed the methodology of our first Processing Schema study , and applied a combined temporal PCA to the Go and NoGo ERPs obtained under caffeine and placebo conditions using the controlled design of Barry et al. (2007) .
That study reported no main effects of caffeine in either the Go or NoGo components. However, topographic effects of caffeine on the components differed, with some effects in Go PN, P2, and P3b, and in NoGo N1-1, P3a, and SW. These were interpreted as confirming caffeine's contribution to differential Go/NoGo processing. However, our subsequent work on PCA misallocation of variance (Barry, De Blasio, Fogarty, & Karamacoska, 2016) suggests that those 2014 caffeine results are not optimal, as a combined PCA across Go and NoGo ERPs from both caffeine and placebo conditions, as used there, is likely to smear both the Go vs. NoGo components, and the different caffeine and placebo effects, towards their mean -resulting in misallocation of variance between the four conditions. This study, aiming to advance the Processing Schema in children, used the controlled design of Barry et al. (2007) with an acute caffeine dose of 80 mg, previously confirmed to generate arousal effects in children (Barry et al., 2009) , to explore arousal effects in the Go/NoGo paradigm. The timing of data collection was based on our finding that significant arousal effects in adults emerged 7 some 20-30 min after caffeine ingestion, and dominated over the next 25-30 min (Barry et al., 2008) .
Further, in light of our recent work on misallocation of variance in combined (across condition) PCAs (Barry, De Blasio, Fogarty, & Karamacoska, 2016) , we used the optimal procedure of separate temporal PCAs for each combination of conditions: Go/Caffeine, Go/Placebo, NoGo/Caffeine, and NoGo/Placebo. Our focal hypothesis was that the components conceptually associated with the stimulus-specific Go/NoGo processing streams in the Schema (components with bolded red or green labels in Fig. 1 ) would be enhanced by caffeine. In addition, any caffeine enhancement of currentlyundifferentiated components early in the processing stream (such as P1, N1-1, PN) would provide new insights, such as signalling either the importance of a common processing stage (i.e., if the enhancement is across Go/NoGo), or the differential involvement of a component/process in the Go or NoGo processing stream (i.e., if the enhancement is stimulus-specific).
Methods

Subjects
Twenty-four children (12 females) were recruited from the local area via advertisements.
Their mean age was 10.6 years (SD 1.5, range 8-12), and 18 subjects were right handed (handedness balanced across gender). Participation was restricted to light to moderate caffeine users, those who regularly consumed 1-2 cans of caffeinated cola equivalents weekly, without reporting any adverse effects of caffeine. They were required to abstain from caffeine and other psychoactive substances for at least 4 h prior to each testing session. Children were screened for neurological disorders, head injuries, learning disabilities and psychiatric conditions. Children with IQ < 85, outside the normal range on the South Australian Spelling Test and Neale Analysis of Reading, and above a T-score of 65 on any measure of the CPRS-48 Conners rating scale, were excluded. The child's participation was voluntary and written informed consent from the parent/guardian was obtained in line with a protocol approved by the joint University of Wollongong/South East Sydney and Illawarra Area Health Service Human Research Ethics Committee, in accordance with the Declaration of Helsinki. Upon completion of the study, children received a certificate, and their parents were recompensed for travel expenses.
Physiological recording
EEG was recorded from 19 sites, using an electrode cap with tin electrodes, referenced to linked ears. Electrode placement was in accord with the international 10-20 system. Vertical and horizontal electro-oculograms (EOGs) were recorded from electrodes above and below the left eye, and beyond the outer canthi of the eyes, respectively. The participant was grounded by a cap electrode at AFz. EEG gain was × 20,000, EOG gain × 5,000, and the data from 0.03 to 35 Hz were sampled by a 16 bit A/D system (AMLAB II) at 512 Hz and recorded for off-line analysis.
Task and procedure
The task was a simple unwarned equiprobable auditory Go/NoGo task. Participants received four blocks of 150 tones of 50 ms duration, with 5 ms rise/fall times, presented via headphones at 60 dB sound pressure level (SPL) with a fixed stimulus onset asynchrony (SOA) of 1,100 ms. Half the tones were 1,000 Hz and half were 1,500 Hz, presented in random order. Participants were required to button-press to one of the tones, with the target frequency, which differed within subject between sessions, balanced between subjects.
When participants arrived at the laboratory the study was described to the child and parent, and if the child agreed to participate, parents read an information sheet, signed a consent form and completed a screening questionnaire. Children were asked to swallow (with water) one of two identical gelatine capsules, containing either 80 mg caffeine or placebo, in a pre-determined randomised order. Both participants and experimenters were blind to the contents of the capsules.
Subjects were then fitted with the physiological measurement equipment, and seated in an airconditioned sound attenuated recording booth.
Recording began approximately 30 min after capsule ingestion. The testing session included the four active Go/NoGo blocks lasting approximately 3 min each, and a number of other tasks not reported here. These segments were separated by brief rest periods. Subjects returned for a second testing session at the same time one week later, when the same procedure was followed and the alternate capsule was administered. On average, the Go/NoGo task began 38.1 min (SD 4.1 min) after capsule ingestion; this period did not differ between the conditions.
Go/NoGo Behavioural Measures
Commission errors to NoGo stimuli, and response omissions (no response to Go stimuli within the SOA), were computed within subject. RT mean (M) and SD for responses within the SOA were calculated, and responses outside the within-subject M ± 1.5 SD RT window were identified as Fast or Delayed RT errors.
ERP quantification
The continuous EEG waveforms were lowpass filtered to 25 Hz (zero phase shift, 24 dB/Octave, FIR), epoched (-100 to +800 ms), and baselined (-100 to 0 ms) offline using Neuroscan software (Compumedics, Version 4.5.1). Single trials containing muscular or other artefact exceeding ±100 µV at any EOG or scalp electrode, or incorrect responses including commission errors to NoGo stimuli, response omissions to Go stimuli (within the SOA), and responses outside the within-subject M ± 1.5 SD RT window, were automatically detected and excluded from further analysis. The remaining trials were averaged within each subject, for each block of each drug (caffeine/placebo) and stimulus (Go/NoGo) condition, forming 16 average ERPs at the 19 electrodes sites for each subject.
Temporal PCA was carried out in MATLAB using Kayser and Tenke's (2003) erpPCA functions (http://psychophysiology.cpmc.columbia.edu/software/), with a heuristic modification from Dien (2010) as discussed in Barry, De Blasio, Fogarty, and Karamacoska (2016) . This was used rather than a sequential temporospatial PCA in order to maximise the variance associated with each analysed component. The input data consisted of the four sets of average ERPs defined above (Go/Caffeine, Go/Placebo, NoGo/Caffeine, NoGo/Placebo), each containing 1,824 cases (4 blocks × 19 EEG electrode sites × 24 subjects), each case being an ERP containing 900 ms of data. For our data recorded at 512 Hz, 900 ms contains 461 data points, the variables for the PCA, leading to a case/variable ratio ~ 4.0. These datasets were subject to four separate temporal PCAs using the covariance matrix with Kaiser normalisation, followed by an unrestricted Varimax rotation (i.e., all 461 factors were VARIMAX-rotated), following Kayser and Tenke (2003) . Starting with those that accounted for the most variance in the data, components were identified as ERPs based on their latency, topography, consistency with the raw ERP waveform, similarity to the published data in Fig.   1 , and known stimulus-specific properties. Only components carrying more than 2 % of the variance were examined further.
Statistical analysis
Behavioural data were analysed using a correlated-samples t-test (Caffeine vs. Placebo), and as caffeine was expected to improve performance, one-way probabilities are reported. The number of accepted trials in the ERPs was checked with a repeated-measures MANOVA (via syntax in IBM SPSS Statistics version 21), with Stimulus (Go, NoGo) and Condition (Caffeine, Placebo) as withinsubjects factors. The two sets of unscaled factor loadings (Caffeine, Placebo) for each processing stream (Go, NoGo) were compared using the Congruence Coefficient (rc; Tucker, 1951) to illuminate latency and amplitude similarities and differences. This is evaluated using a rule of thumb: equality is indicated by rc ≥ 0.95, and fair similarity by .85 ≤ rc ≤ .94 (Lorenzo-Seva & ten Berge, 2006) . versus the mean of the hemispheres (L/R). For the temporal PN, F3/4, C3/4, P3/4 were replaced by F7/8, T7/8, P7/8, respectively. As the contrasts were all planned and did not exceed the degrees of freedom for effect, no Bonferroni-type adjustment of α levels was required (Tabachnick & Fiddell, 2013) . All contrasts reported had df = (1, 23).
For each component, significant topographic contrasts across conditions were taken as the best estimate defining the component. Significant interactions of these defining contrasts with Condition were taken to indicate Caffeine effects on the component. For example, if a component showed a significant parietal effect across conditions (i.e., F < P), this was taken as a defining characteristic of that component. If that parietal topography then interacted with Condition, this was considered to reflect a Caffeine effect on the component, while interactions of Condition with other (non-defining) topographic contrasts were considered random topographic effects.
Results
Behavioural data
As shown in Table 1 , caffeine was associated with significant reductions in Go omission errors and mean Go RT. Fast and delayed Go RT errors, NoGo commission errors, and Go RT variability each failed to show any significant effect of caffeine. 
ERPs
Across the four blocks, on average there were 173.9 (SD = 41.0) accepted trials in each mean Go ERP, and 183.1 (SD = 46.0) in each mean NoGo ERP, with no participant contributing less than 89 trials. There were more accepted trials in caffeine (M = 187.7, SD = 42.3) than placebo (M = 169.4, SD = 43.3; F = 5.39, p = .030, ηp 2 = .19), but these numbers did not differ with stimulus condition. Panel A of Fig. 2 shows the midline mean ERPs for Go and NoGo stimuli (across caffeine and placebo). There was a clear frontal P1 around 70 ms, and a frontal N1 around 100 ms, followed by a very large frontal N2 around 220 ms. This was followed by marked P3s near 330 ms, with apparent topographic differences between the small NoGo (central) and later large Go (parietal) responses. P3 was followed by a classic frontal-negative/parietal-positive SW, and NoGo LP.
Caffeine appeared to have both early and late effects on the ERPs to Go stimuli (see Fig. 2 Correlations between the reconstituted (Panel E) and raw (Panel B) Go waveforms at each of the midline sites ranged between .92 and .99 for Caffeine and .93 and .98 for Placebo; all were highly significant (p < .001), confirming their good approximation to the raw data. Go components in each condition. The factor number, peak latency, and unique variance associated with each component are also presented with the headmaps. Component labels reflect their temporal sequence, latency, similarity to the components identified in the raw ERPs, and the previous separate PCA outcomes found for children in this paradigm , but with the addition of an initial P1. P1 was followed by N1-1 and the PN (dominant in temporal regions). These were followed, in latency order, by components identifiable as N2c, P3b, and a LN. For each component, the Congruence Coefficient rc, and the topographic correlation r(17) between the 19 pairs of electrodes, are listed between the two sets of headmaps. The Congruence coefficients indicated that Go PN and N2c timings and amplitudes were similar in Caffeine and Placebo, while all other components were identical. All topographic correlations between the Caffeine and Placebo Go components were significant, r(17) ≥ .77, p < .001, indicating highly-similar components in each condition.
Figure 3 about here
Go component topographies
The MANOVA indicated that P1 was strongly frontal (F > P: F = 33.36, p < .001, ηP 2 = .59; C < F/P: F = 5.04, p = .035, ηP 2 = .18), and somewhat reduced centrally in the hemispheres (C < F/P × M < L/R: F = 3.66, p = .068, ηP 2 = .14) and significantly so in the central right (C < F/P × L < R: F = 5.00, p = .035, ηP 2 = .18). These results and other Go component MANOVA results are shown in Table 2 . Note the shading there indicating a directional reversal in the corresponding P1 effect (i.e., the central reduction, not increase), and the statistical equivalence of the effect with two directional reversals (i.e., the central hemispheric reduction). In order to save space, subsequent results here omit statistics from the text as they are reported in Table 2 . N1-1 was somewhat larger in the frontal (cf. parietal) region, and this frontal enhancement was significantly larger in the hemispheres compared with the midline, and was reduced centrally compared with frontal and parietal regions, particularly in the left compared with the right hemisphere. PN was more negative frontally, and in the hemispheres, particularly the right hemisphere; frontally, PN was larger on the right, and centrally, it was larger in the hemispheres, reflecting its defining temporal topography. N2c was frontocentral and midline dominant; the frontal dominance was somewhat enhanced in the midline, and the central dominance was significantly enhanced in the midline. P3b was centroparietal, and the parietal enhancement was largest in the midline. The LN was reduced centrally, and enhanced in the midline and left hemisphere; the LN midline enhancement was frontocentral, and the left hemisphere enhancement was central. These significant topographic effects across Condition are taken as the defining characteristics of the Go components. Table 2 , Caffeine was associated in the Go P1 with a slight increase in positivity that was significantly smaller at the vertex, and there was some central reduction in N1-1. These effects on the non-defining topographic contrasts can be seen in a comparison of the two rows of headmaps in Fig. 3 . With PN, Caffeine reduced negativity frontally, in the midline and right hemisphere, but enhanced the defining relative central hemispheric negativity. N2c was globally enhanced by Caffeine, particularly in frontal and hemispheric regions.
P3b was also globally enhanced, and the LN showed some left central increase with Caffeine.
NoGo PCA outcomes
Of the first nine factors in variance order from each NoGo PCA, eight appeared to correspond. Component 7 in placebo and component 7 in caffeine each carried more than 2 % variance, but neither had a matching component in the other condition. Individually the corresponding components accounted for > 2 % variance, and together they accounted for 85.6 % of the total variance in Caffeine, and 82.1 % in Placebo. The sums of these components are displayed as virtual ERPs in Fig. 2 (panels D and F) , corresponding to the adjacent raw NoGo ERPs. The PCAs appear to have produced virtual NoGo ERPs that match the raw ERPs (compare right panels with left). Correlations between the reconstituted (Panel F) and raw (Panel C) mean NoGo waveforms at each of the midline sites ranged between .96 and .98 for caffeine and between .95 and .99 for placebo; all were highly significant (p < .001), confirming their good approximation to the raw data. Components were identified in terms of their timing, sequence, and similarity to the raw ERP components and those previously identified. P1 was again followed by N1-1 and PN. These were followed, in latency order, by components identifiable from the revised Child Schema as N2b, fN2c, P3a, NegSW, and LP. The Congruence coefficients in Fig. 4 indicated that NoGo PN was similar between Caffeine and Placebo, while all other components showed equivalence between conditions, except for N2b, which differed largely because of its magnitude difference. All topographic correlations between the Caffeine and Placebo NoGo components were significant, r(17) ≥ .71, p < .001, indicating that there were highly-similar components in both conditions. Table 3 , MANOVAs indicated that NoGo P1 was frontal, larger in the midline, and reduced centrally on the right and in the midline. N1-1 was strongly frontal and dominant in the midline; central negativity was larger on the right and largest at the vertex. PN was larger frontally, particularly in the midline, and in the hemispheres, particularly the right hemisphere; centrally, PN was larger in the hemispheres, confirming its defining temporal topography. The NoGo N2b was frontocentral and dominant on the right, with the frontal dominance enhanced in the midline. The NoGo fN2c was frontal, with some central right enhancement. P3a was frontal and midline, and there was a frontocentral enhancement in the midline. NegSW was strongly frontal, somewhat larger on the left, and largest in the frontal midline. The LP was centroparietal, and reduced in the midline; the midline reduction was frontocentral, and there was some frontal left reduction. Significant topographic effects across Condition are taken as the defining characteristics of the NoGo components. 
NoGo component caffeine effects
In the NoGo components, Caffeine was associated in P1 with a relative reduction in the left hemisphere and central right region; see the bottom part of Table 3 and compare the two rows of headmaps in Fig. 4 . In N1-1, Caffeine produced an increase centrally, in the midline, and at the vertex; enhancing most of its defining topography. With PN, Caffeine reduced negativity in the right hemisphere, and frontally in the midline; overall, the component became less negative in Caffeine.
N2b was globally enhanced by Caffeine, particularly in frontal and hemispheric regions, but least at the vertex. The NoGo fN2c component was significantly reduced globally by Caffeine, particularly frontocentrally, in the midline, and frontocentrally in the midline. NoGo P3a was reduced by Caffeine centrally, particularly in the left hemisphere. With Caffeine, NegSW showed some frontal increase, and the LP showed some hemispheric increase; both these effects are in aspects of the defining topographies.
Discussion
The PCA components obtained separately for Go and NoGo under caffeine and placebo broadly match those recently used to generate our updated Processing Schema for children in this equiprobable paradigm ; see Fig. 1 ). In addition, a consistent but small P1 was obtained here. This component is not always reported, but is often seen with < 2 % of the variance, our usual cut-off for detailed consideration. The mean topographic results obtained here, presented in the upper halves of Tables 2 and 3, appear to be a general match to those obtained previously, suggesting that the present child sample is typical/representative of this population.
Caffeine effects
In this double-blind placebo-controlled cross-over study, caffeine was associated with a reduction in Go omissions. RT was reduced by caffeine compared with placebo, but RT variability did not change with caffeine. That is, caffeine improved Go performance significantly in accuracy and speed, but had no effect on response consistency. There was no reduction in NoGo commission errors, but this might reflect a floor effect, as the NoGo task was performed quite efficiently (< 5 % errors on average).
Of most interest here is the effect of caffeine on the ERP components. Of the Go components, P1 and N1-1 both had localised changes that did not reflect the overall topography. The frontal and midline negativity of PN was reduced by caffeine, but more importantly, the defining temporal (cf. vertex) negativity was enhanced. N2c and P3b were both globally enhanced by caffeine (see Fig. 3 ), but LN showed no significant effects.
In the NoGo components, P1 again had localised changes that did not reflect the overall defining topography. NoGo N1-1 was enhanced in most of its defining regions, particularly in the midline and vertex regions. PN became globally less negative in caffeine, although the defining temporal negativity was unaffected. Caffeine generally enhanced N2b as predicted, and reduced fN2c. P3a was topographically reduced by caffeine, in regions beyond its defining topography, suggesting that it is not engaged with N2b in conflict monitoring/premotor inhibitory processing; perhaps it may be involved in motor inhibition (see Pires et al., 2014) . The NegSW and LP showed non-significant effects in aspects of their defining topography.
Effects on schema stages
Overall, our major hypotheses were supported. We had proposed that active control-related components of our Schema's segregation into separate Go and NoGo processing streams should be differentially enhanced by caffeine. For ease of understanding, we address these findings in terms of the stages in the Child Processing Schema shown in Fig. 1. 
Sensory processing and Go/NoGo categorization
The lack of substantial caffeine effects in P1 is compatible with its Schema placement in a pre-categorization period of processing bridging from early sensory processing, and common to all stimuli.
The defining topographic features of the N1-1 were mostly enhanced by caffeine in NoGo, but not Go. In contrast, the defining aspects of the Go PN were significantly enhanced by caffeine, while caffeine had no effect in the case of the NoGo PN. These outcomes are compatible with expectations of components marking Go/NoGo categorization stages -the same components occur in response to both Go and NoGo, but are differentially enhanced by caffeine when active categorization of the NoGo (N1-1) or Go (PN) stimulus is emerging. This interpretation of the NoGo N1 is compatible with the view of it as marking the NoGo decision (Filipović, Jahanshahi, & Rothwell, 2000; Kirmizi-Alsan et al., 2006) .
Go-specific processing
As described in the Introduction, in the Go processing stream, N2c and P3b are considered to be markers of active response processing. Each of these components was significantly enhanced by caffeine, strongly supporting their placement and functioning in the Go processing stream.
NoGo-specific processing
In the NoGo stream, N2b has been recognised as the critical marker of active inhibitory control, being related to reduced numbers of commission errors. This component was significantly enhanced by caffeine, strongly supporting its placement and function in the NoGo processing stream.
Unexpected results for three other NoGo components are of interest. The NoGo fN2c, which occurs in the same timeframe as the Go N2c but with a different topography (and hence is likely to be a different component), was the only component with significantly decreased global amplitude with caffeine. We had not reported this component before our recent upgrade of the Child Schema with improved PCA methodology , and are yet to determine its function in this paradigm. Speculatively, the present caffeine effect suggests that fN2c may be a marker of postinhibition evaluation: caffeine increases N2b (marking greater inhibition), and perhaps fN2c reduces because there is less need for evaluation of the success of inhibition. The next component showing an unexpected effect was NoGo NegSW. This component has been previously found to be larger with greater commission error rates, and its occurrence after the mean Go RT led to its identification as a late NoGo evaluative process , perhaps associated with the Correct Response Negativity/ERN (e.g., Vidal, Hasbroucq, Grapperon, & Bonnet, 2000) . The topography of the NegSW is strongly frontal, and here caffeine was found to enhance that frontal activity, in line with our prediction. However, this failed to reach statistical significance; but note that if a one-way test was used rather than the two-way F-test, it would have shown a significant amplitude increase with caffeine. Similarly, the hemispheric LP, posited to mark the early cessation of processing in the NoGo stream (in the absence of a response requirement; , was nonsignificantly enhanced hemispherically by caffeine; again, this would have been significant if a oneway test had been used.
Schema modifications
In summary, we found significant enhancements of Go PN, N2c, and P3b, and NoGo N1-1 and N2b with caffeine, as well as non-significant but supportive enhancements in NoGo NegSW and LP. There was also a novel finding of a reduction in NoGo fN2c amplitude with caffeine that could provide insights into its functional role in this paradigm. In the light of these findings, some minor modifications of the Child Processing Schema are warranted. Fig. 5 incorporates these updates (cf. the schema in Fig. 1) . The new bolding of the P1 and NoGo fN2c components indicates our greater confidence in their stability, derived from their present confirmation in a new child sample with separate condition PCAs, and from ERPs collected under placebo and caffeine.
Figure 5 about here
In the Child Processing Schema, P1 is now confirmed as marking early sensory processing that does not distinguish between Go and NoGo. Caffeine enhanced the defining midline and vertex topography of the NoGo N1-1 component, suggesting that identification and categorization of the NoGo stimulus, and its reflection in this component, has begun, and that this active processing has been amplified by caffeine. In contrast, Go PN had its defining temporal topography enhanced by caffeine, suggesting that PN marks the categorization phase for the Go stimulus at the end of sensory processing. Accordingly, these early Go/NoGo updates are indicated in the model by the red/green colour labels for NoGo N1-1 and Go PN (respectively) in these processing stages, while maintaining the same labels in black for the unaffected condition. The "categorization" stage is now terminated directly after PN; subsequent processing is marked by different Go and NoGo components. In the post-categorization Go processing stream, caffeine amplified N2c and P3b as expected, confirming their active processing. Although all nine core LN sites were more negative in caffeine than placebo, this failed to approach statistical significance, suggesting that its proposed function -a late post-20 response error evaluation -was not affected by arousal. Hence, this novel child component needs further research in future studies.
In the post-categorization NoGo stream, caffeine enhanced N2b, the primary indicator of the control process of response inhibition in this paradigm Fogarty et al., 2018) , as predicted. We have not resolved the function of the child P3a in previous studies (e.g., Barry et al., 2018) , and the present study has yielded no new insights. There were no significant caffeine effects in either the NegSW or LP, respectively postulated to reflect a late error-evaluation process and general reduction in cortical activation after the earlier trial completion in NoGo (cf. Go) processing . However, the implications of the non-significant effects of caffeine support their active roles within the Child Schema. In addition, one other finding is of some interest -the reduced NoGo fN2c in caffeine compared to placebo. When first reported in our previous child study (as NoGo N2c; Barry et al., 2018) , it was regarded as some sort of "place holder" in the NoGo processing stream in this population, corresponding to the timing of the Go N2c rather than its function. Perhaps this component reflects the child's uncertainty or conflict regarding Go/NoGo processing (Botvinick et al., 2001; Nieuwenhuis et al., 2003) . Alternatively, it might reflect some activation of the Go response preparation carried through in the Go stream with the N2c/P3b processing, but not completed in successful NoGo trials. Its reduction in caffeine could then reflect a second active inhibition process in children. This possibility needs further investigation, but the confirmation of this component here warrants its inclusion in bold type in the revised Child Schema shown in Fig. 5 .
Strengths and limitations
The major strength of this study lies not in the study of caffeine per se, but in the novel use of caffeine as a specific amplifying factor to test the active-processing aspects of the separate Go and NoGo streams of the Child Processing Schema. The Schema itself is also novel -it is the only coherent conceptualisation of the processing chain encompassing all ERP components found in the first 800 ms poststimulus in this paradigm. In turn, this paradigm sits at the midpoint of all simple two-choice active-response paradigms, and has potential to bring new insights into this major class of cognitive processing designs.
Further novelty arises in this study with the application of separate PCAs carried out on the Go and NoGo datasets rather than the traditional combined PCA on the joint Go/NoGo data. This avoids the misallocation of variance between the Go and NoGo components, which tends to blend aspects of the separate Go vs. NoGo components, obscuring their real differences (Barry, De Blasio, Fogarty, & Karamacoska, 2016) . This blending would have been further exacerbated if PCAs had been based on data including both Caffeine and Placebo responses. This significant improvement in our novel PCA approach rules out meaningful comparisons with previous PCA studies in the child/caffeine area, and sets the benchmark for future research.
Although our gender-matched sample of children tested in a double-blind repeated-measures cross-over design, with N = 24, is quite substantial in the context of the vast bulk of the child ERP literature, we would have more confidence in the reliability of our results if the sample was larger.
This issue should be considered in future work.
Conclusions and future directions
This study utilised the stimulant properties of caffeine to increase the arousal state of children undertaking the equiprobable auditory Go/NoGo task. We hypothesised that this would enhance ERP components reflecting active control processing in the task, as modelled in the Processing Schema for children first proposed by Barry and De Blasio (2015) , and recently updated by . This general hypothesis was supported, and additional caffeine/placebo differences were used to further extend the Child Schema. Caffeine thus appears to be a useful tool for future studies of control processes in a range of paradigms and across the lifespan, and further studies of the Processing Schema appear promising.
The equiprobable auditory Go/NoGo task used to generate the Processing Schema, and employed here, is at the probability midpoint between traditional high target probability Go/NoGo (target p > .5) and traditional low target probability Oddball tasks (target p < .5), and thus may be 22 regarded as a proxy for these (and indeed, all) two-choice decision tasks. Future studies are necessary to illuminate the applicability of the Schema across this range, but it should serve as a beginning point for a detailed understanding of the sequential processes involved, and their ERP component markers. We have begun such extensions in relation to the classic Oddball task in adults (Fogarty, Barry, & Steiner, in press) , and extensions to the rare NoGo variants of the Go/NoGo task are in progress. Improved understanding of the control processes and their indices in these tasks, and their trajectory across the lifespan, might provide important markers for the detection, treatment, and/or monitoring of control related dysfunction in clinical and subclinical populations. Barry et al. (2018) . Early common stages of sensory processing and categorization lead to the separation of two processing streams. Note that pale font identifies components that are infrequently extracted in child data; their corresponding headmaps are also omitted, except for that of the NoGo fN2c which was extracted in Barry et al.'s (2018) sample. Note the stimulus-specific indicators in the categorization components (N1-1 and PN), and the reclassification of the P1 and NoGo fN2c as robust components (indicated via bold font). Caff > Plac × C < F/P × L < R 3.11 .091 .12
Caff > Plac × C > F/P × M < L/R 7.64 .011 .25 16.20 .001 .41
Note. Caff = caffeine; Plac = placebo; F = frontal; P = parietal; C = central; F/P = frontoparietal mean; L = left; R = right; M = midline; L/R = hemispheric mean. Bold effects are significant and filled cells indicate a reversal of one relationship indicator in the corresponding effect. Two relationship reversals within an effect represents a statistically-equivalent effect (e.g., Caff > Plac × C < F/P × M < L/R ≡ Caff > Plac × C > F/P × M > L/R). 
